Annual EBITDA
$1.18 M
+$40.76 M+102.99%
December 31, 2023
Summary
- As of February 7, 2025, AQST annual EBITDA is $1.18 million, with the most recent change of +$40.76 million (+102.99%) on December 31, 2023.
- During the last 3 years, AQST annual EBITDA has risen by +$40.50 million (+103.01%).
- AQST annual EBITDA is now -53.92% below its all-time high of $2.56 million, reached on December 31, 2017.
Performance
AQST EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$7.15 M
-$8.81 M-532.15%
September 30, 2024
Summary
- As of February 7, 2025, AQST quarterly EBITDA is -$7.15 million, with the most recent change of -$8.81 million (-532.15%) on September 30, 2024.
- Over the past year, AQST quarterly EBITDA has dropped by -$6.55 million (-1092.00%).
- AQST quarterly EBITDA is now -162.86% below its all-time high of $11.38 million, reached on September 30, 2017.
Performance
AQST Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$18.23 M
-$6.55 M-56.13%
September 30, 2024
Summary
- As of February 7, 2025, AQST TTM EBITDA is -$18.23 million, with the most recent change of -$6.55 million (-56.13%) on September 30, 2024.
- Over the past year, AQST TTM EBITDA has dropped by -$13.46 million (-282.72%).
- AQST TTM EBITDA is now -288.51% below its all-time high of $9.67 million, reached on September 30, 2017.
Performance
AQST TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AQST EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +103.0% | -1092.0% | -282.7% |
| 3 y3 years | +103.0% | -1092.0% | -282.7% |
| 5 y5 years | +102.3% | -1092.0% | -282.7% |
AQST EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +102.6% | -172.4% | +71.0% | -1641.9% | +66.2% |
| 5 y | 5-year | at high | +102.2% | -172.4% | +71.0% | -1641.9% | +66.8% |
| alltime | all time | -53.9% | +102.2% | -162.9% | +78.8% | -288.5% | +73.8% |
Aquestive Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.15 M(-532.1%) | -$18.23 M(+56.1%) |
| Jun 2024 | - | $1.66 M(-119.7%) | -$11.67 M(-31.8%) |
| Mar 2024 | - | -$8.42 M(+95.5%) | -$17.12 M(-1548.3%) |
| Dec 2023 | $1.18 M(-103.0%) | -$4.31 M(+617.8%) | $1.18 M(-124.8%) |
| Sep 2023 | - | -$600.00 K(-84.2%) | -$4.76 M(-61.6%) |
| Jun 2023 | - | -$3.79 M(-138.4%) | -$12.41 M(-40.0%) |
| Mar 2023 | - | $9.88 M(-196.4%) | -$20.69 M(-47.7%) |
| Dec 2022 | -$39.58 M(-12.3%) | -$10.25 M(+24.2%) | -$39.58 M(-26.6%) |
| Sep 2022 | - | -$8.25 M(-31.6%) | -$53.95 M(+1.9%) |
| Jun 2022 | - | -$12.06 M(+33.9%) | -$52.93 M(+14.4%) |
| Mar 2022 | - | -$9.01 M(-63.4%) | -$46.27 M(+2.8%) |
| Dec 2021 | -$45.11 M(+14.7%) | -$24.63 M(+240.5%) | -$45.03 M(+28.9%) |
| Sep 2021 | - | -$7.23 M(+33.9%) | -$34.94 M(-14.4%) |
| Jun 2021 | - | -$5.40 M(-30.5%) | -$40.83 M(+19.3%) |
| Mar 2021 | - | -$7.77 M(-46.5%) | -$34.22 M(-13.0%) |
| Dec 2020 | -$39.32 M | -$14.54 M(+10.8%) | -$39.32 M(+15.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$13.12 M(-1184.3%) | -$34.00 M(-5.3%) |
| Jun 2020 | - | $1.21 M(-109.4%) | -$35.89 M(-34.6%) |
| Mar 2020 | - | -$12.87 M(+39.7%) | -$54.88 M(+1.6%) |
| Dec 2019 | -$54.02 M(+7.1%) | -$9.22 M(-38.6%) | -$54.02 M(-3.7%) |
| Sep 2019 | - | -$15.02 M(-15.5%) | -$56.09 M(+5.0%) |
| Jun 2019 | - | -$17.77 M(+47.9%) | -$53.43 M(-23.1%) |
| Mar 2019 | - | -$12.02 M(+6.5%) | -$69.45 M(+37.7%) |
| Dec 2018 | -$50.43 M(-2066.0%) | -$11.28 M(-8.7%) | -$50.45 M(+9.0%) |
| Sep 2018 | - | -$12.36 M(-63.4%) | -$46.27 M(+105.3%) |
| Jun 2018 | - | -$33.79 M(-584.2%) | -$22.54 M(-373.0%) |
| Mar 2018 | - | $6.98 M(-198.3%) | $8.26 M(+221.8%) |
| Dec 2017 | $2.56 M(+493.8%) | -$7.10 M(-162.4%) | $2.56 M(-73.5%) |
| Sep 2017 | - | $11.38 M(-479.4%) | $9.67 M(-665.4%) |
| Jun 2017 | - | -$3.00 M(-332.7%) | -$1.71 M(-232.7%) |
| Mar 2017 | - | $1.29 M | $1.29 M |
| Dec 2016 | $432.00 K | - | - |
FAQ
- What is Aquestive Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Aquestive Therapeutics?
- What is Aquestive Therapeutics annual EBITDA year-on-year change?
- What is Aquestive Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aquestive Therapeutics?
- What is Aquestive Therapeutics quarterly EBITDA year-on-year change?
- What is Aquestive Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Aquestive Therapeutics?
- What is Aquestive Therapeutics TTM EBITDA year-on-year change?
What is Aquestive Therapeutics annual EBITDA?
The current annual EBITDA of AQST is $1.18 M
What is the all time high annual EBITDA for Aquestive Therapeutics?
Aquestive Therapeutics all-time high annual EBITDA is $2.56 M
What is Aquestive Therapeutics annual EBITDA year-on-year change?
Over the past year, AQST annual EBITDA has changed by +$40.76 M (+102.99%)
What is Aquestive Therapeutics quarterly EBITDA?
The current quarterly EBITDA of AQST is -$7.15 M
What is the all time high quarterly EBITDA for Aquestive Therapeutics?
Aquestive Therapeutics all-time high quarterly EBITDA is $11.38 M
What is Aquestive Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AQST quarterly EBITDA has changed by -$6.55 M (-1092.00%)
What is Aquestive Therapeutics TTM EBITDA?
The current TTM EBITDA of AQST is -$18.23 M
What is the all time high TTM EBITDA for Aquestive Therapeutics?
Aquestive Therapeutics all-time high TTM EBITDA is $9.67 M
What is Aquestive Therapeutics TTM EBITDA year-on-year change?
Over the past year, AQST TTM EBITDA has changed by -$13.46 M (-282.72%)